Year 2016 / Volume 108 / Number 4
Submission and tracking of manuscripts
Instructions to authors

Submission and tracking

REED Journal

REED Journal

Play video

Year 2016 / Volume 108 / Number 4

Special Article

Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva


Cristóbal de la Coba Ortiz, Federico Argüelles Arias, Carlos Martín de Argila de Prados, Javier Júdez Gutiérrez, Antonio Linares Rodríguez, Aida Ortega Alonso, Enrique Rodríguez de Santiago, Manuel Rodríguez-Téllez, María Isabel Vera Mendoza, Lara Aguilera Castro, Ángel Álvarez Sánchez, Raúl Jesús Andrade Bellido, Fidencio Bao Pérez, Manuel Castro Fernández, Froilán Giganto Tomé,

Introduction: In the last few years a significant number of papers have related the use of proton-pump inhibitors (PPIs) to potential serious adverse effects that have resulted in social unrest. Objective: The goal of this paper was to provide a literature review for the development of an institutional position statement by Sociedad Española de Patología Digestiva (SEPD) regarding the safety of long-term PPI use. Material and methods: A comprehensive review of the literature was performed to draw conclusions based on a critical assessment of the following: a) current PPI indications; b) vitamin B12 deficiency and neurological disorders; c) magnesium deficiency; d) bone fractures; e) enteric infection and pneumonia; f) interactions with thienopyridine derivatives; e) complications in cirrhotic patients. Results: Current PPI indications have remained unchanged for years now, and are well established. A general screening of vitamin B12 levels is not recommended for all patients on a PPI; however, it does seem necessary that magnesium levels be measured at therapy onset, and then monitored in subjects on other drugs that may induce hypomagnesemia. A higher risk for bone fractures is present, even though causality cannot be concluded for this association. The association between PPIs and infection with Clostridium difficile is mild to moderate, and the risk for pneumonia is low. In patients with cardiovascular risk receiving thienopyridines derivatives it is prudent to adequately consider gastrointestinal and cardiovascular risks, given the absence of definitive evidence regardin potential drug-drug interactions; if gastrointestinal risk is found to be moderate or high, effective prevention should be in place with a PPI. PPIs should be cautiously indicated in patients with decompensated cirrhosis. Conclusions: PPIs are safe drugs whose benefits outweigh their potential side effects both short-term and long-term, provided their indication, dosage, and duration are appropriate.

Valoración del lector: Valora este artículo:
Share Button
Send by e-mail

New comment

Security code:
CAPTCHA code image
Speak the codeChange the code


17/03/2020 20:58:06
muy buen articulo

20/10/2016 1:45:47
Tema de gran interés.

23/05/2016 18:31:08

Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
© 2020 The Spanish Journal of Gastroenterology